Skip to main content

Table 2 Adverse events related to vaccine and IL-2

From: Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma

Vaccine-related AEs Maximum Grade Patients
System Adverse Events   N = 25 %
Constitutional Fever 1 8 32
  Pain at injection site 1 4 16
  Injection site reaction 1 3 12
  Myalgia 1 1 4
  Chills 1 1 4
IL-2-related AEs    
Cardiovascular Cardiopulmonary arrest 4 1 4
  Elevated troponin 4 1 4
  Hypotension 4 9 36
  Ventricular tachycardia 3 1 4
  Acidosis 4 1 4
Electrolyte Hyperglycemia 3 4 16
  Hypocalcemia 3 1 4
  Hyponatremia 3 11 44
  Hypophosphatemia 3 3 12
Gastro-intestinal Ischemic bowel 4 1 4
Hematologic Anemia 3 2 8
  Neutropenia 3 1 4
  Thrombocytopenia 3 4 16
Hepatic Elevated transaminases 3 1 4
  Hyperbilirubinemia 3 3 12
Neurologic Confusion 3 3 12
  Syncope 3 2 8
Pulmonary Dyspnea 3 1 4
Renal Elevated creatinine 3 22 88
  Oliguria 3 2 8
Systemic Fatigue 3 1 4